$196.34 Million in Sales Expected for Invacare Co. (NYSE:IVC) This Quarter

Brokerages expect Invacare Co. (NYSE:IVC – Get Rating) to announce sales of $196.34 million for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Invacare’s earnings, with the highest sales estimate coming in at $197.38 million and the lowest estimate coming in at $195.30 million. Invacare reported sales of $196.20 million during the same quarter last year, which indicates a positive year over year growth rate of 0.1%. The business is scheduled to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Invacare will report full year sales of $872.01 million for the current fiscal year, with estimates ranging from $863.60 million to $880.42 million. For the next financial year, analysts expect that the business will report sales of $910.31 million, with estimates ranging from $889.50 million to $931.11 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Invacare.

Invacare (NYSE:IVC – Get Rating) last issued its earnings results on Tuesday, March 8th. The health services provider reported $0.08 EPS for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.06. Invacare had a negative net margin of 5.22% and a negative return on equity of 9.22%. During the same period in the previous year, the business earned ($0.10) earnings per share.

Separately, StockNews.com initiated coverage on shares of Invacare in a research report on Thursday, March 31st. They issued a “hold” rating for the company. Two analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $8.50.

In related news, CFO Kathleen P. Leneghan acquired 20,000 shares of the business’s stock in a transaction dated Friday, March 11th. The shares were acquired at an average cost of $1.49 per share, for a total transaction of $29,800.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Matthew E. Monaghan purchased 33,000 shares of the business’s stock in a transaction that occurred on Friday, March 11th. The stock was acquired at an average price of $1.49 per share, for a total transaction of $49,170.00. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 63,000 shares of company stock worth $93,870. 6.20% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC acquired a new stake in Invacare in the fourth quarter valued at approximately $40,000. Walleye Trading LLC acquired a new stake in Invacare in the fourth quarter valued at approximately $44,000. Vantage Consulting Group Inc acquired a new stake in Invacare in the third quarter valued at approximately $50,000. Maryland State Retirement & Pension System acquired a new stake in Invacare in the third quarter valued at approximately $67,000. Finally, Panagora Asset Management Inc. acquired a new stake in Invacare in the fourth quarter valued at approximately $77,000. Hedge funds and other institutional investors own 99.25% of the company’s stock.

Shares of NYSE IVC opened at $1.44 on Friday. The firm has a 50-day simple moving average of $1.71 and a 200-day simple moving average of $2.71. The stock has a market capitalization of $50.48 million, a price-to-earnings ratio of -1.09 and a beta of 1.04. The company has a quick ratio of 0.98, a current ratio of 1.56 and a debt-to-equity ratio of 1.69. Invacare has a 52 week low of $1.38 and a 52 week high of $9.23.

About Invacare (Get Rating)

Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide. The company offers mobility and seating products, such as power wheelchairs under the Invacare TDX brand; custom manual wheelchairs under the Invacare, Invacare Top End, and Küschall brand names; and seating and positioning products under the Invacare brand, as well as custom molded seat modules under the PinDot brand.

See Also